We serve big pharma, midsize biotech, startups and academics by leveraging our ecosystem and expertise in radiopharmaceutical discovery to accelerate preclinical programs into clinical translation.
RPT Labworks is a contract research organization (CRO) based in the USA that provides end-to-end preclinical radiopharmaceutical theranostics (RPT) development, optimization and testing services.
Imaging radionuclides:
64Cu, 18F, 68Ga, 123I, 124I, 111In, 52Mn, 203Pb, 44Sc, 99mTc, 86Y, 89Zr
Therapeutic radionuclides:
225Ac, 67Cu, 125I, 131I, 177Lu, 212Pb, 223Ra, 161Tb, 90Y
Accuracy is at the core of everything we do. Our team leverages decades of expertise in the design and execution of imaging, efficacy, dosimetry, and radiation toxicity studies. Through meticulously maintained and calibrated equipment and vetted protocols, we deliver results that drive confident decision-making.
Our integrated teams and proven workflows accelerate radiopharmaceutical programs from discovery to clinic. By ensuring quality data and regulatory-ready studies, we help you reduce risk, save time, and bring life-saving therapies to patients sooner. Whether you’re optimizing a candidate or preparing for IND submission, we streamline every step. It is out goal to begin your studies as soon as possible and to provide a comprehensive report 2-4 weeks following study completion.
We recognize that priorities can shift and pivoting is necessary. That’s why we share updates at key phases of your study and adapt quickly to new requests along the way.
With multiple decades of combined experience in radiopharmaceutical theranostics, our team combines backgrounds in nuclear medicine, molecular imaging, cancer biology, and medical physics. We know what it takes to design studies that deliver reproducible, clinically relevant results.
We are radionuclide- and vector-agnostic and equipped to manage complex and unconventional studies. From custom conjugation and radiolabeling to in vitro assays, disease modeling, quantitative imaging, dosimetry, efficacy, radiation toxicity and ex vivo biodistribution, we offer end-to-end preclinical services.
